Patrys (ASX:PAB)
ASX announcement history & article coverage
Transparent by design.
Announcments by Patrys (ASX:PAB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Investor Presentation
Patrys advances IV quetiapine program toward FDA 505(b)(2) pathway and 2027 clinical milestones
Investor Webinar
Patrys CEO to present at MST biotech and healthcare investor webinar
Date of AGM and Closing Date for Director Nominations
Notification of cessation of securities - PAB
Patrys Completes Cohort 1 Dosing and Follow-Up
Patrys completes Cohort 1 dosing for RLS-2202 Phase 1a trial
Appendix 4E Variance Report
Annual Report - 30 June 2025
Patrys advances RLS-2202 trial after Reliis acquisition but warns of funding needs
Appendix 4G and Corporate Governance Statement
First Participants Dosed in RLS-2202 Phase 1A Clinical Trial
Patrys doses first participants in Phase 1a trial of intravenous quetiapine
PAB Establishes Clinical Advisory Committee
Patrys forms international advisory committee to guide RLS-2202 delirium trials
Appendix 4E - Preliminary Final Report
Ethics Approval Secured for Phase 1A Clinical Trial
Patrys secures ethics approval for Phase 1A clinical trial of RLS-2202, dosing to start this quarter
Investor Presentation - TechKnow Invest Roadshow
Patrys advances injectable quetiapine for delirium with accelerated FDA pathway and strong IP protection
Appendix 4C - Quarterly - 30 June 2026